1. Signaling Pathways
  2. Neuronal Signaling
  3. Transthyretin (TTR)
  4. Transthyretin (TTR) Inhibitor

Transthyretin (TTR) Inhibitor

Transthyretin (TTR) Inhibitors (9):

Cat. No. Product Name Effect Purity
  • HY-N1957
    Gamma-Mangostin
    Inhibitor 99.90%
    Gamma-Mangostin is a novel competitive 5-hydroxytryptamine 2A (5-HT2A) receptor antagonist and potent epoxidase 2 (COX-2) inhibitor, as well as a transthyroxin protein (TTR) profibrosis inhibitor. Gamma-Mangostin binds to the thyroxine (T4)-binding sites and stabilized the TTR tetramer. Gamma-Mangostin inhibits [3H] spiperone binding to cultured rat aortic myocytes (IC50=3.5 nM) and reduces The perfusion pressure response of rat coronary artery to 5-HT2A (IC50=0.32 μM). Gamma-Mangostin has anti-inflammatory, antibacterial, antioxidant and anticancer activities, and can be used in the study of metabolic disorders such as diabetes.
  • HY-148089A
    Eplontersen sodium
    Inhibitor
    Eplontersen sodium is a triantennary N-acetyl galactosamine (GalNAc3-7a)-conjugated antisense oligonucleotide targeting transthyretin (TTR) mRNA to inhibit production of both variant and wild-type TTR protein. Misfolded TTR induces amyloid fibrils formation in the heart and peripheral nerves, leads to amyloid TTR (ATTR) amyloidosis diseases.
  • HY-132590A
    Revusiran sodium
    Inhibitor
    Revusiran sodium is a 1st-generation short interfering RNA, which directed against transthyretin (TTR) mRNA. Revusiran sodium can be used for transthyretin (TTR)-mediated amyloidosis research.
  • HY-160612
    Transthyretin-IN-2
    Inhibitor
    Transthyretin-IN-2 (Compound 36) is a transthyretin (TTR) amyloidsis inhibitor, with IC50 and pIC50 values of 1.31 μM and 5.88 μM. Transthyretin-IN-2 can be used for the research of TTR amyloidosis diseases.
  • HY-153609
    AS-Patisiran sodium
    Inhibitor
    AS-Patisiran sodium is an antisense strand of Patisiran. Patisiran is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran can be used for the research of hereditary TTR amyloidosis.
  • HY-148089
    Eplontersen
    Inhibitor
    Eplontersen is a triantennary N-acetyl galactosamine (GalNAc3-7a)-conjugated antisense oligonucleotide targeting transthyretin (TTR) mRNA to inhibit production of both variant and wild-type TTR protein. Misfolded TTR induces amyloid fibrils formation in the heart and peripheral nerves, leads to amyloid TTR (ATTR) amyloidosis diseases.
  • HY-153577
    WT-TTR inhibitor 1
    Inhibitor 98.03%
    WT-TTR inhibitor 1 (Compound 21) is a wild-type Transthyretin (WT-TTR) inhibitor with 29.05% inhibition at 100 μM.
  • HY-155299
    PITB
    Inhibitor
    PITB is a selective and orally active transthyretin (TTR) aggregation inhibitor. PITB can be used for transthyretin amyloidosis (ATTR) disease research.
  • HY-112974
    Inotersen
    Inhibitor
    Inotersen is an antisense oligonucleotide that inhibits hepatic production of transthyretin (TTR).